Clinical trials: Pharmacogenetic Variation
Adverse Drug Events, Adverse Drug Reactions
Pharmacogenetic Testing Among Home Health Patients
Patients meeting eligibility criteria will be randomized into two groups, one receiving pharmacogenetic testing and the other not receiving pharmacogenetic testing.
- Conditions
- Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED
- Trial name
- NCT02378220
- Testing
- Pharmacogenetic testing
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Genelex Corporation
Depression, Depressive Disorder
Cytochrome P450-2D6 Screening Among Elderly Using Antidepressants (CYSCE)
Depression is common among elderly with an estimated prevalence of 5%. Due to ageing the national burden will double in the coming decade.
- Conditions
- Depression, Depressive Disorder, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant, Intermediate Metabolizer Due to Cytochrome P450 CYP2D6 Variant
- Trial name
- CYSCE (NCT01778907)
- Testing
- Genotype information accompanied by a drug dosing advice
- Where
- 11 sites in Netherlands
- Volunteers
- 202 people
- Sponsor
- University of Groningen
Breast Cancer, Metastatic Breast Cancer
Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response
The metabolism of anticancer drugs is influenced by genetic variants that affect their bioavailability and toxicity. In the case of antibody-drug conjugates (ADCs), such as sacituzumab-govitecan (SG), trastuzumab-deruxtecan…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Drug-Related Side Effects and Adverse Reactions, Pharmacogenetic Variant
- Trial name
- NCT07582887
- Testing
- Sacituzumab Govitecan, Trastuzumab deruxtecan, Datopotamab Deruxtecan
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
Psoriasis, Psoriatic Arthritis (PsA)
Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors
This retrospective observational study aims to evaluate the long-term survival of biologic therapies in adult patients with moderate-to-severe cutaneous psoriasis, with or without psoriatic arthritis, over a period of up to 10…
- Conditions
- Psoriasis, Psoriatic Arthritis (PsA), Cardiovascular Risk Factors, Metabolic Syndrome (MetS)
- Trial name
- GENBIOPSO (NCT07041112)
- Testing
- Biologic therapy for psoriasis
- Where
- Spain
- Volunteers
- 1,000 people
- Sponsor
- Juan Ruano Ruiz
Asthma
The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations
This study is looking at the effects of certain long-acting bronchodilators on patients with asthma who have specific genetic variations.
- Trial name
- GABLE (NCT00706446)
- Testing
- tiotropium bromide, Salmeterol, Formoterol
- Where
- 2 sites in United States
- Volunteers
- 255 people
- Sponsor
- Brigham and Women's Hospital